Brookline starts Celsion at buy; PT $9

Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25.

Celsion is focused on clinical-stage oncology products and platform technologies that can be used for targeting cancer.

ThermoDox is a heat-labile liposome containing the chemotherapy, doxorubicin, and is being evaluated in a Phase 3 study in liver cancer patients. Patient enrollment is complete and first interim results are expected in the second half of 2019, writes analyst Kumaraguru Raja.

Celsion’s GEN-1 delivers IL-12 plasmids to cancers and is being tested in a Phase 1/2 study in ovarian cancer patients. Mr. Raja said the Phase 1b OVATION 1 study has demonstrated clinical efficacy and improved progression free survival. The Phase 1 portion will report dose escalation results in the second half of 2019, he added.

Mr. Raja said Celsion’s delivery platforms have the potential to carry chemotherapy or DNA/RNA to cancer lesions. Regulatory approvals in initial indications of liver and ovarian cancers should lead to expansion into other solid tumors, he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.